文献速递妇科肿瘤

BRCA1/2突变携带者输卵管切除后延迟卵巢切除与双侧输卵管卵巢切除的生活质量比较:非随机对照试验

Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项多中心非随机偏好对照试验纳入577名25-45岁绝经前BRCA1/2突变携带者,比较风险降低性输卵管切除(RRS)后延迟卵巢切除与风险降低性输卵管卵巢切除(RRSO)对绝经相关生活质量的影响。提示RRS可能带来更好的绝经相关生活质量,但肿瘤安全性仍在随访评估中。

要点

  • RRS后延迟卵巢切除在绝经相关生活质量上优于RRSO,无论是否使用激素替代治疗。
  • 未用激素替代治疗时,RRSO后1年内Greene评分较RRS高6.7分(95%CI 5.0-8.4)。
  • 使用激素替代治疗时,RRSO与RRS的评分差异仍为3.6分(95%CI 2.3-4.8)。

核心结论

  • 非随机对照试验结果提示,BRCA1/2突变携带者接受RRS后延迟卵巢切除的绝经相关生活质量优于RRSO,无论是否使用激素替代治疗。
  • 该策略的肿瘤安全性尚待国际随访研究评估。

研究设计与样本

  • 在荷兰所有大学医院及少数大型综合医院开展,共纳入577名25-45岁绝经前、已完成生育、未接受癌症治疗的BRCA1/2突变携带者。
  • 394例接受RRS,154例接受RRSO;297例(51.5%)为BRCA1突变,280例(48.5%)为BRCA2突变;平均(SD)年龄37.2(3.5)岁。

临床怎么用

  • 对于完成生育的BRCA1/2突变携带者,RRS后延迟卵巢切除可能作为延迟绝经、改善绝经相关生活质量的选项。
  • RRSO后推荐无禁忌症者使用激素替代治疗。
  • 该策略的肿瘤安全性尚未确定,需等待国际随访研究结果。

局限性

  • 为非随机对照偏好试验,可能存在选择偏倚。
  • 肿瘤安全性结局尚未报告,需进一步随访评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Most women with a BRCA1/2 pathogenic variant undergo premature menopause with potential short- and long-term morbidity due to the current method of ovarian carcinoma prevention: risk-reducing salpingo-oophorectomy (RRSO). Because the fallopian tubes play a key role in ovarian cancer pathogenesis, salpingectomy with delayed oophorectomy may be a novel risk-reducing strategy with benefits of delaying menopause. OBJECTIVE: To compare menopause-related quality of life after risk-reducing salpingectomy (RRS) with delayed oophorectomy with RRSO in carriers of the BRCA1/2 pathogenic variant. DESIGN, SETTING, AND PARTICIPANTS: A multicenter nonrandomized controlled preference trial (TUBA study), with patient recruitment between January 16, 2015, and November 7, 2019, and follow-up at 3 and 12 months after surgery was conducted in all Dutch university hospitals and a few large general hospitals. In the Netherlands, RRSO is predominantly performed in these hospitals. Patients at the clinical genetics or gynecology department between the ages of 25 and 40 years (BRCA1) or 25 to 45 years (BRCA2) who were premenopausal, had completed childbearing, and were undergoing no current treatment for cancer were eligible. INTERVENTIONS: Risk-reducing salpingo-oophorectomy at currently recommended age or RRS after completed childbearing with delayed oophorectomy. After RRSO was performed, hormone replacement therapy was recommended for women without contraindications. MAIN OUTCOMES AND MEASURES: Menopause-related quality of life as assessed by the Greene Climacteric Scale, with a higher scale sum (range, 0-63) representing more climacteric symptoms. Secondary outcomes were health-related quality of life, sexual functioning and distress, cancer worry, decisional regret, and surgical outcomes. RESULTS: A total of 577 women (mean [SD] age, 37.2 [3.5] years) were enrolled: 297 (51.5%) were pathogenic BRCA1 variant carriers and 280 (48.5%) were BRCA2 pathogenic variant carriers. At the time of analysis, 394 patients had undergone RRS and 154 had undergone RRSO. Without hormone replacement therapy, the adjusted mean increase from the baseline score on the Greene Climacteric Scale was 6.7 (95% CI, 5.0-8.4; P < .001) points higher during 1 year after RRSO than after RRS. After RRSO with hormone replacement therapy, the difference was 3.6 points (95% CI, 2.3-4.8; P < .001) compared with RRS. CONCLUSIONS AND RELEVANCE: Results of this nonrandomized controlled trial suggest that patients have better menopause-related quality of life after RRS than after RRSO, regardless of hormone replacement therapy. An international follow-up study is currently evaluating the oncologic safety of this therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02321228.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Steenbeek MP, Harmsen MG, Hoogerbrugge N, et al. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial. JAMA Oncol. 2021. PMID: 34081085. doi:10.1001/jamaoncol.2021.1590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。